Raymond James Financial
TEVA icon

Raymond James Financial’s Teva Pharmaceuticals TEVA Stock Holding History

Raymond James Financial’s Portfolio TEVA Stock Details TEVA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$54.7M Sell
1,816,715
-162,487
-8% -$5.23M 0.02% 808
2025
Q4 		$61.8M Buy
1,979,202
+335,239
+20% +$8.26M 0.02% 716
2025
Q3 		$33.2M Buy
1,643,963
+158,879
+11% +$2.79M 0.01% 1057
2025
Q2 		$24.9M Sell
1,485,084
-133,023
-8% -$2.15M 0.01% 1201
2025
Q1 		$24.9M Sell
1,618,107
-147,486
-8% -$2.63M 0.01% 1143
2024
Q4 		$38.9M Buy
+1,765,593
New +$32.1M 0.01% 874

Other funds holding TEVA

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
HIIFS
Harel Insurance Investments & Financial Services Ramat Gan, Israel $20.6B AUM 59.59% 1-Year Est. Return
PF
Phoenix Financial Givatayim, Israel $10.5B AUM 49.21% 1-Year Est. Return
MMH
Menora Mivtachim Holdings Ramat Gan, Israel $21.1B AUM 40.03% 1-Year Est. Return
WCM Investment Management
WCM Investment Management Laguna Beach, California $43.8B AUM 42.28% 1-Year Est. Return
CI
Clal Insurance Tel-Aviv, Israel $16.6B AUM 68.34% 1-Year Est. Return
MIFH
Migdal Insurance & Financial Holdings Petach Tikva, Israel $11.5B AUM 52.5% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
LIM
Lingotto Investment Management London, United Kingdom $4.67B AUM 70.24% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Raymond James Financial's TEVA Position: Q1 2026 in Review

Raymond James Financial reduced its Teva Pharmaceuticals (TEVA) stake by 8.2% in Q1 2026, selling an estimated $5.23M and leaving 1,816,715 shares worth $54.7M. The position accounts for 0.02% of the portfolio, ranked #808.

Raymond James Financial first reported a position in TEVA in Q4 2024 and has held it in 6 quarters since. The position peaked at $61.8M in Q4 2025. 651 funds tracked by Wall St. Rank hold TEVA as of Q1 2026.

  • Raymond James Financial held 1,816,715 shares of Teva Pharmaceuticals worth $54.7M as of Q1 2026.
  • Raymond James Financial sold 162,487 Teva Pharmaceuticals shares in Q1 2026, an estimated $5.23M.
  • Teva Pharmaceuticals made up 0.02% of Raymond James Financial's portfolio in Q1 2026, its #808 holding.
  • Raymond James Financial first reported a position in Teva Pharmaceuticals in Q4 2024 and has held it in 6 quarters since.
  • Raymond James Financial's Teva Pharmaceuticals position peaked at $61.8M in Q4 2025.
  • 651 funds tracked by Wall St. Rank held Teva Pharmaceuticals as of Q1 2026.

Based on Raymond James Financial's 13F filing for Q1 2026, filed 14 May 2026.